Valuation: Legend Biotech Corporation

Capitalization 7.27B 6.21B 5.79B 5.35B 9.96B 623B 11.14B 69.28B 26.36B 291B 27.27B 26.71B 1,065B P/E ratio 2025 *
-42.6x
P/E ratio 2026 * 83.4x
Enterprise value 6.75B 5.76B 5.37B 4.97B 9.25B 578B 10.34B 64.29B 24.46B 270B 25.31B 24.78B 989B EV / Sales 2025 *
6.6x
EV / Sales 2026 * 4.16x
Free-Float
98.8%
Yield 2025 *
-
Yield 2026 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day+5.24%
1 week+9.87%
Current month+11.17%
1 month+13.44%
3 months+22.99%
6 months+20.40%
Current year+21.25%
More quotes
1 week 34.64
Extreme 34.64
39.49
1 month 32.42
Extreme 32.42
39.49
Current year 27.34
Extreme 27.34
40
1 year 27.34
Extreme 27.34
60.87
3 years 27.34
Extreme 27.34
77.32
5 years 23.41
Extreme 23.41
77.32
10 years 23.41
Extreme 23.41
77.32
More quotes
Manager TitleAgeSince
Chief Executive Officer 52 2020-09-20
Director of Finance/CFO 40 2025-01-01
Chief Tech/Sci/R&D Officer 47 2023-04-10
Director TitleAgeSince
Chairman 56 2020-11-05
Director/Board Member 52 2021-12-29
Director/Board Member 68 2020-04-30
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
+5.24%+9.87%-15.53%-29.61% 7.27B
+1.94%+2.95%+10.13%+31.67% 33.32B
-0.99%-0.71%+87.06%-36.75% 27.79B
+0.11%+3.25%+38.84%-34.30% 27.52B
+7.61%+9.37%+215.56%+2,325.49% 18.37B
+0.34%-1.80%+37.28%+288.99% 18.32B
-0.77%-0.39%+141.09%-66.65% 13.43B
+2.02%+8.40%-20.65%-43.91% 13.23B
-1.37%+2.07%+189.96%+364.81% 12.55B
+1.29%-0.52%+98.96%+100.23% 12.02B
Average +0.84%+3.59%+78.27%+290.00% 18.38B
Weighted average by Cap. +0.60%+2.82%+73.72%+278.56%
See all sector performances

Financials

2025 *2026 *
Net sales 1.02B 874M 814M 753M 1.4B 87.69B 1.57B 9.75B 3.71B 40.97B 3.84B 3.76B 150B 1.57B 1.34B 1.25B 1.15B 2.15B 134B 2.4B 14.95B 5.69B 62.82B 5.88B 5.76B 230B
Net income -143M -122M -114M -105M -196M -12.26B -219M -1.36B -518M -5.73B -536M -525M -20.96B 177M 151M 141M 130M 242M 15.15B 271M 1.68B 641M 7.08B 663M 649M 25.9B
Net Debt -524M -447M -417M -386M -718M -44.89B -802M -4.99B -1.9B -20.97B -1.96B -1.92B -76.73B -745M -636M -593M -548M -1.02B -63.86B -1.14B -7.1B -2.7B -29.83B -2.79B -2.74B -109B
More financial data * Estimated data
Logo Legend Biotech Corporation
Legend Biotech Corporation is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.
Employees
2,700
More about the company
Date Price Change Volume
25-07-10 39.40 $ -0.14% 273,981
25-07-09 39.46 $ +5.24% 1,295,206
25-07-08 37.49 $ +4.52% 1,893,395
25-07-07 35.87 $ +0.65% 1,488,904
25-07-03 35.64 $ -0.75% 604,100

Delayed Quote Nasdaq, July 09, 2025 at 04:00 pm EDT

More quotes
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
39.46USD
Average target price
75.07USD
Spread / Average Target
+90.26%
Consensus

Quarterly revenue - Rate of surprise